LENZ Therapeutics

LENZ

Market cap $572M

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Launched VIZZ™  (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LENZ Therapeutics, Inc. shares fell ~30% after a reported adverse event with VIZZ, but I do not view this as thesis-destroying. VIZZ offers superior efficacy and duration versus competitors, yet faces potentially slow market adoption and entrenched alternatives like glasses, contacts, and LASIK. LENZ's $3 billion market opportunity is plausible but hinges on shifting consumer behavior and overcoming negative sentiment from recent safety news.